Lonza Group is a Swiss multinational, chemical and biotechnology company headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was founded under that name at the end of the 19th century in Switzerland. The company provides product development services for the pharmaceutical and biological industries, including organic, fine and performance chemicals, custom biopharmaceutical manufacturing, chemical synthesis capabilities, detection systems and services for the bioscience sector.
Video Lonza Group
History
Lonza was founded in 1897 in the small town of Switzerland, Gampel, located in the Valais canton, taking its name from the nearby river. Initially the company produces electricity used to produce chemicals such as calcium carbide. Lonza moved to Visp's neighbor (where he maintained the production site today) in 1909 and started producing synthetic fertilizers, and moved to vitamins, acids, intermediates, and additives. In 1974, the group joined the aluminum company Alusuisse, after which the group moved into the biotech sector. Lonza de-joined from Alusuisse-Lonza Group in 1999 and registered on SWX Swiss Exchange.
The company grew in the United States in 1969 and acquired a smaller biopharmaceutical unit in recent years. In 1996, Lonza acquired Celltech Biologics and began producing mammalian cell cultures and monoclonal antibodies. In October 2011, Lonza acquired American company, Arch Chemicals, for $ 1.4 billion, as a result of becoming the world's largest producer of biocides. On August 15, 2016, the group announced its intention to acquire Nutraceuticals InterHealth, a leader in research, development, manufacture and marketing of value-added nutrients for use in dietary supplements. The acquisition of a US-based company will be worth up to US $ 300 million . In December 2016, the company announced it would acquire Capsugel for US $ 5.5 billion , from a private equity firm KKR.
Lonza is involved in biological manufacturing with several pharmaceutical companies. Lonza entered into a partnership with Teva in 2009 to develop and produce biosimilars. In 2010, they made a deal with GlaxoSmithKline to produce therapeutic monoclonal antibodies. In 2014, Lonza entered into an agreement with Bristol-Myers Squibb to produce two biological drugs. Lonza also manufactures Imbruvica for Pharmaclikics and Mydicar for Celladon. In 2015, Lonza contracted with Alexion to build a new facility dedicated to manufacturing Alexion. In 2017, Lonza and Sanofi are partnering to build a new facility for biological production.
Maps Lonza Group
Company structure
In 2018, Lonza's chief executive officer is Richard Ridinger, while CEO for 2010-2013 is Stefan Borgas.
Business operations
By 2018, Lonza has twenty-four self-described main sites in the United States, India, Czech Republic, Belgium, Spain, China, France, South Africa, Switzerland, Singapore, Mexico, Japan, Brazil, and the UK. Kingdom. The bookkeeping of this site shows a significant change from the 2016 self-description, which lists sixteen major sites. Attendance in India was established in Genome Valley, where the soil was damaged in 2011.
In 2018, Lonza opened a 300,000 square foot facility in the United States in Pearland, Texas (suburb of Houston). It is one of four sites focused on cell and gene therapy, the other three being in Portsmouth, New Hampshire; Geleen, Netherlands; and Singapore.
In 2016, the company employs about 10,000 people, in about 18 countries. By 2018, jobs are listed as 14,500 in 100 sites.
References
External links
- Official website
Source of the article : Wikipedia
0 Comments